Post hoc adjustment for HbA1C and other traditional renal risk factors did not have a major influence on renal benefit by liraglutide, semaglutide, or dulaglutide in CVOTs, nor were there differences in glycemic control in the AWARD-766 study
Dose: 5mg subcutaneous injection weekly Expected side effects: Moderate nausea (55-65% of users), appetite significantly reduced, possible constipation or diarrhea Expected weight loss: 5-8 pounds cumulative (8-13 pounds total since start) Critical actions: Implement anti-nausea strategies, maintain protein despite reduced appetite, begin light exercise if tolerated Cold foods become essential during this phase
Eur J Clin Pharmacol 2005;61:567-72
Retatrutide and tirzepatide are often compared because they represent the next wave of metabolic medications, but theyre not equally accessible
Weight loss injections are now available in Colorado Springs
Medicine and Science in Sports and Exercise